Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620953 | 0.85 | KDM4E (0.49) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL236467 | 0.84 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL6002635 | 0.82 | KDM4E (0.46) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL9678739 | 0.80 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL31023504 | 0.79 | KDM4E (0.48) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL6289416 | 0.78 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL14471947 | 0.78 | JAK2 (0.47) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL25375133 | 0.78 | CSNK1D (0.49) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL14471980 | 0.78 | P2RY12 (0.44) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL11457347 | 0.77 | KDM4E (0.57) | NPC1RAB9ASMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | IMBACH PATRICIA | 2010-03-18 | — | — | US | disclosed |
| EP-2079745-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-3925385-A | 6-Carbethoxy-3,7-disubstitutedpyrazolo{8 1,5a{9 pyrimidines | VIRATEK, INC., A CORP. OF DE. | 1975-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | PRKCA, PRKACA, MAP3K19 | NPC1 2457/4885RAB9A 1142/4885SMN1; SMN2 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.